Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
MOE Key Laboratory of Bioinformatics, School of Life Sciences, Tsinghua University, Beijing, China.
Br J Haematol. 2020 Sep;190(5):741-752. doi: 10.1111/bjh.16569. Epub 2020 Mar 10.
To investigate the cellular mechanisms of multiple myeloma (MM), we used liquid chromatography-tandem mass spectrometry for proteomics analysis of CD138 plasma cells from patients with MM and healthy controls. We found that the 60-kDa heat shock protein (HSP60, also known as HSPD1) was significantly upregulated in myeloma cells. HSP60 is an important chaperone protein that regulates the homeostasis of mitochondrial proteins and maintains mitochondrial function. Knockdown (KD) of HSP60 in myeloma cells resulted in inhibition of proliferation and reduced the quality of the mitochondria. Mitochondrial stress tests showed that HSP60 KD inhibited glycolysis and mitochondrial activity. Metabolomics showed a decrease in glycolysis and tricarboxylic acid cycle metabolites, and inhibited the formation of creatine and phosphocreatine by the reaction of S-adenosylmethionine (SAM) with amino acids mediated by demethyladenosine transferase 1, mitochondrial (TFB1M) and reduced energy storage substances. Moreover, HSP60 silencing influenced the synthesis of ribonucleotides and nicotinamide adenine dinucleotide phosphate (NADPH) by the pentose phosphate pathway to inhibit cell proliferation. HSP60 KD inhibited 5' adenosine monophosphate-activated protein kinase (AMPK), which inhibited the key enzyme 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), effecting the metabolism of fatty acids by inhibiting malonyl-coenzyme A. Our data suggest that reduced HSP60 expression alters metabolic reprogramming in MM, inhibits tumour progression and reduces mitochondrial-dependent biosynthesis, suggesting that HSP60 is a potential therapeutic target for MM treatment.
为了研究多发性骨髓瘤(MM)的细胞机制,我们使用液相色谱-串联质谱法对 MM 患者和健康对照者的 CD138 浆细胞进行蛋白质组学分析。我们发现,热休克蛋白 60kDa(HSP60,也称为 HSPD1)在骨髓瘤细胞中显著上调。HSP60 是一种重要的伴侣蛋白,可调节线粒体蛋白的内稳态并维持线粒体功能。骨髓瘤细胞中 HSP60 的敲低(KD)导致增殖抑制和线粒体质量降低。线粒体应激测试表明,HSP60 KD 抑制糖酵解和线粒体活性。代谢组学显示糖酵解和三羧酸循环代谢物减少,并且 S-腺苷甲硫氨酸(SAM)与氨基酸反应生成的肌酸和磷酸肌酸被 demethyladenosine transferase 1,mitochondrial(TFB1M)抑制,能量储存物质减少。此外,HSP60 沉默影响戊糖磷酸途径合成核苷酸和烟酰胺腺嘌呤二核苷酸磷酸(NADPH),从而抑制细胞增殖。HSP60 KD 抑制 5' 腺苷单磷酸激活蛋白激酶(AMPK),从而抑制关键酶 6-磷酸果糖-2-激酶/果糖-2,6-二磷酸酶 3(PFKFB3),通过抑制丙二酰辅酶 A 抑制脂肪酸的代谢。我们的数据表明,HSP60 表达的降低改变了 MM 中的代谢重编程,抑制肿瘤进展并减少线粒体依赖性生物合成,表明 HSP60 是 MM 治疗的潜在治疗靶点。